|
|
|
Prosonix Wins Award at Major Conference- DDL-20 |
 |
 |
 |
|
Written by Graham Ruecroft
|
|
Sunday, 13 December 2009 00:00 |
|
Prosonix was delighted to win the best industrial poster award at Europe's premier conference and exhibition dedicated to pulmonary and nasal drug delivery, namely Drug Delivery to the Lungs - DDL20, which took place from Wednesday 9th - Friday 11th December 2009, in its 20th year!
|
|
Last Updated on Wednesday, 24 February 2010 13:53 |
|
Read more...
|
|
Prosonix Attains International Quality Approval |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 26 June 2009 08:02 |
|
 Prosonix (Oxford, UK) is pleased to announce that it has achieved accreditation to the Quality Management standard ISO 9001:2008 following a recent audit of business systems and procedures by independent external auditors SGS (UK) Ltd.
|
|
Last Updated on Friday, 26 June 2009 10:51 |
|
Read more...
|
|
|
Prosonix Announce The Launch Of UMAX technology |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 05 March 2010 00:00 |
 Prosonix is pleased to announce the launch of its UMAX® technology - an acronym for Ultrasound Mediated Amorphous to Crystalline transition - which is a new disruptive particle engineering technology set to revolutionise respiratory medicine. The proprietary technology has now been demonstrated on over 30 generic and novel drug molecules and combination products.
|
|
Last Updated on Friday, 05 March 2010 10:59 |
|
Read more...
|
|
Prosonix and Syrris launch SonoLab |
|
|
|
|
Written by Graham Ruecroft
|
|
Tuesday, 17 March 2009 16:24 |
|
Following the announcement in December 2008 that Prosonix and Syrris (Royston, UK) entered a new marketing partnership to position Syrris as the prime channel to market for Prosonix's new SonoLabTM laboratory scale sonocrystallization and sonoprocessing equipment, the two companies are pleased to announce the launch of the proprietary |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 Next > End >>
|
|
Page 1 of 8 |
David Hipkiss, CEO of Prosonix, recently spoke to CHEM-anager Europe about the company's endeavours in using its proprietary sonocrystallization and particle engineering technologies for Making Better Medicines. Within this discussion David spoke at length about the application of proprietary pharmaceutical ultrasonic particle engineering technologies, ultrasonic process chemistry and processing equipment to deliver sustainable value to the pharmaceutical industry.
